atg-031

ATG-031 is a first-in-class humanized monoclonal antibody targeting CD24, a cell surface protein overexpressed on many tumor cells. By binding to CD24, ATG-031 blocks its interaction with Siglec-10 on tumor-associated macrophages (TAMs), thereby inhibiting the "don't eat me" signal that allows cancer cells to evade immune surveillance. This blockade enhances macrophage-mediated phagocytosis of cancer cells and promotes cytotoxic T-cell function in the tumor microenvironment. Preclinical studies have shown that ATG-031 can repolarize M2 macrophages toward an antitumor M1 phenotype and induce significant tumor regression both as monotherapy and in combination with immune checkpoint inhibitors or chemotherapy[3][6][8]. The drug is being developed for advanced solid tumors and B-cell non-Hodgkin lymphoma.

Other names

anti-CD24 monoclonal antibody ATG-031anti-CD-24 monoclonal antibody ATG-031anti-CD 24 monoclonal antibody ATG-031humanized anti-CD24 mAb